How to Stack SS-31 + MOTS-C (Exact Dosing Protocol)

Your mitochondria are not just power generators. They are also quality control systems, and those two functions are handled by completely different mechanisms, which is exactly why stacking SS-31 and MOTS-c makes biological sense even though no human trial has ever tested them together.

To understand why this stack works the way it does, you need the full picture first.

Mitochondria produce energy by running electrons down a chain of protein complexes along the inner membrane, and that process generates something called ATP, which is the actual fuel your cells use for everything. The problem is that this process also leaks reactive oxygen species, which are unstable molecules that damage the very membrane they are produced at. Over time that damage compounds, the membrane becomes less structured, energy production drops, and you get what researchers describe as mitochondrial dysfunction.

That dysfunction sits underneath a lot of what we call aging.

SS-31 works at the structural level. It binds to something called cardiolipin, which is a lipid molecule found almost exclusively in the inner mitochondrial membrane and whose job is to stabilize the protein complexes that actually run the electron transport chain. When cardiolipin is oxidized or disorganized, those complexes drift apart and efficiency collapses. SS-31 slots into cardiolipin and holds the architecture together.

Because it is binding a lipid and not a receptor, there is nothing to desensitize. You cannot wear it out. The longest human trial ran SS-31 continuously for 168 weeks in patients with Barth syndrome, which is a genetic mitochondrial cardiomyopathy, and those patients showed progressive improvement across the entire period with no tolerance development whatsoever.

That is why the cycling recommendation for SS-31 is precautionary rather than mechanistic. The biology does not require it.

MOTS-c works somewhere completely different. It is a peptide that your own mitochondria actually produce, encoded in the mitochondrial genome, and its job is to regulate gene expression in the nucleus in response to metabolic stress. When energy availability drops or cellular stress rises, MOTS-c gets released, travels to the nucleus, and activates pathways that improve how the cell handles fuel and clears cellular debris.

The key pathway it drives runs through something called AMPK, which is essentially the cell's low-fuel sensor, and through PGC-1 alpha, which is a master regulator of mitochondrial quality. When MOTS-c activates that cascade, it improves how mitochondria process fuel and reduces the production of reactive oxygen species without changing the total number of mitochondria present.

That last part matters because it tells you MOTS-c is improving efficiency per mitochondrion, not just adding more of them.

Now here is where the dosing logic comes from. SS-31 has a half-life of roughly two hours in human plasma, which means it clears fast and you need daily exposure to maintain structural support at the membrane. The reason lower doses work is that SS-31 concentrates approximately five thousand fold at the inner mitochondrial membrane relative to plasma levels, so even a small circulating amount reaches therapeutic concentration exactly where it needs to be. A phase 2 trial directly compared 4 milligrams against 40 milligrams and found no advantage to the higher dose, which is why the working range sits between 1 and 5 milligrams per day rather than the higher doses sometimes discussed.

MOTS-c clears from plasma even faster, but its mechanism does not depend on sustained plasma levels. It works through gene expression changes, and gene expression changes persist after the peptide is gone. A 2021 study in Nature Communications found that loading daily and then dropping to three times per week maintained all the functional benefits, which tells you the downstream signaling outlasts the molecule itself. That is why Monday, Wednesday, Friday dosing holds without requiring daily administration.

The reason these two compounds layer well together is that their mechanisms genuinely do not compete. SS-31 operates at the physical structure of the membrane. MOTS-c operates at the level of gene expression and metabolic signaling. One is structural, one is regulatory, and they are working on different parts of the same system.

The closest published evidence for this kind of combination comes from a 2020 study pairing SS-31 with NMN in aged mice, where the two compounds showed synergistic effects on cardiac metabolism and function beyond what either produced alone. SS-31 and NMN also target non-overlapping mechanisms, so that result is at least consistent with the logic being applied here, even though it is not direct evidence for this specific stack.

For a starting protocol, the numbers that tend to work in practice are 2 milligrams of SS-31 daily and 10 milligrams of MOTS-c across the week split into three doses. If you are new to either compound, starting at half those amounts for the first two to four weeks gives you a reasonable on-ramp. If you are working with more significant age-related decline, the upper range would be 5 milligrams SS-31 daily and 15 milligrams MOTS-c weekly.

The 8 to 12 week on, 4 to 8 week off structure is reasonable caution given the absence of long-term human data at these doses. Not because the biology demands a break, but because we do not yet have the data to confidently say it does not.

Most people expect dosing protocols to be about finding the right receptor dose and then cycling off to reset sensitivity. SS-31 and MOTS-c do not fit that model at all, and understanding why changes how you think about using them. The question is not how to prevent tolerance. The question is whether you are giving the repair process enough time to actually complete, and whether you are maintaining the signaling conditions that keep the downstream changes running.

Those are different questions, and they point toward a different kind of patience.

---

References

1. Thompson WR, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a mitochondrial cardiomyopathy. Genetics in Medicine. 2024;267:101133. 168-week continuous SS-31 at 40mg daily with progressive improvement and no tolerance. Source
2. Butler J, et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF phase 2 trial. Journal of Cardiac Failure. 2020;265:429-437. 4mg vs 40mg comparison: 40mg showed no advantage over 4mg. Source
3. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. 3x/week maintenance dosing preserved all benefits after daily loading. Source
4. Gudiksen A, et al. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1alpha/AMPK-dependent manner. Free Radical Biology and Medicine. 2026;246:682-696. MOTS-C improves mitochondrial quality without increasing content, reduces ROS. Source
5. Whitson JA, et al. SS-31 and NMN: Two paths to improve metabolism and function in aged hearts. Aging Cell. 2020;1910:e13213. Closest published combination data: SS-31 + NMN synergy in aged mice. Source
6. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;213:443-454. Original MOTS-C dosing data: 0.5mg/kg chronic, 5mg/kg acute in mice. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness